Announcements Trials
Browse Landscape

Phase

Phase 1 2

Status

Completed 2

Sponsor Class

NIH 2

Study Type

Interventional 2

Sponsor

Cancer Type

Other hematologic neoplasm 2Lymphoid 2Myeloid 1

Conditions

Breast Neoplasms 17Ovarian Neoplasms 15Triple Negative Breast Neoplasms 10Neoplasms 8Fallopian Tube Neoplasms 8Neoplasm Metastasis 7Carcinoma, Non-Small-Cell Lung 5Pancreatic Neoplasms 4Brain Neoplasms 4Astrocytoma 4Stomach Neoplasms 3Recurrence 3Prostatic Neoplasms 3Precursor Cell Lymphoblastic Leukemia-Lymphoma 3Lymphoma 3Gliosarcoma 3Glioblastoma 3Colonic Neoplasms 3Breast Neoplasms, Male 3Uterine Cervical Neoplasms 2Small Cell Lung Carcinoma 2Rectal Neoplasms 2Precursor T-Cell Lymphoblastic Leukemia-Lymphoma 2Oligodendroglioma 2Melanoma 2Medulloblastoma 2Lymphoma, T-Cell 2Lymphoma, Mantle-Cell 2Lymphoma, Follicular 2Lung Neoplasms 2

Interventions

Cytarabine 60Etoposide 24Daunorubicin 24Filgrastim 19Idarubicin 16Mitoxantrone 13Busulfan 12tipifarnib 11Gemtuzumab 10fludarabine phosphate 9Peripheral Blood Stem Cell Transplantation 9Cyclophosphamide 9Flow Cytometry 8Clofarabine 8Azacitidine 8sargramostim 7Methotrexate 7Gene Expression Profiling 7Topotecan 6Cyclosporine 6valspodar 5alvocidib 5Radiotherapy 5Granulocyte Colony-Stimulating Factor 5aldesleukin 4Observation 4Bortezomib 4Arsenic Trioxide 4Antilymphocyte Serum 4Whole-Body Irradiation 3

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Completed × Leukemia, Myelomonocytic, Acute × veliparib × Clear all
NCT01139970 2025-11-20

Veliparib and Temozolomide in Treating Patients With Acute Leukemia

National Cancer Institute (NCI)

Phase 1 Completed
66 enrolled
LymphoidOther hematologic neoplasm

Burkitt Lymphoma, Leukemia, Myeloid, Acute, Leukemia, Myelomonocytic, Chronic, Leukemia, Myelomonocytic, Acute, Precursor Cell Lymphoblastic Leukemia-Lymphoma, Precursor T-Cell Lymphoblastic Leukemia-Lymphoma

NCT00588991 2025-04-02

Veliparib and Topotecan With or Without Carboplatin in Treating Patients With Relapsed or Refractory Acute Leukemia, High-Risk Myelodysplasia, or Aggressive Myeloproliferative Disorders

National Cancer Institute (NCI)

Phase 1 Completed
12 enrolled
LymphoidMyeloidOther hematologic neoplasm

Leukemia, Erythroblastic, Acute, Leukemia, Megakaryoblastic, Acute, Leukemia, Monocytic, Acute, Myelodysplastic Syndromes, Polycythemia Vera, Thrombocythemia, Essential, Leukemia, Myelogenous, Chronic, BCR-ABL Positive, Leukemia, Myeloid, Acute, Leukemia, Myelomonocytic, Chronic, Leukemia, Myelomonocytic, Acute, Hematologic Neoplasms, Precursor Cell Lymphoblastic Leukemia-Lymphoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡